You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: Generx+, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  2. N/A

    SBC: Generx+, Inc.            Topic: N/A

    N/A

    STTR Phase II 2000 Department of Health and Human ServicesNational Institutes of Health
  3. N/A

    SBC: Generx+, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  4. N/A

    SBC: Generx+, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  5. SUPERCONDUCTING MAGNET FOR MICROCOIL NMR

    SBC: American Magnetics, Inc.            Topic: N/A

    DESCRIPTION (Verbatim from the Applicant's Abstract): The specific aims of this Phase I STTR project, proposed by the American Magnetics, Inc. in partnership with the MIT Francis Bitter Magnet Laboratory, are: 1) experimental demonstration of feasibility of innovative design and operation features applicable to NMR Nb3Sn-magnet/cryocooler systems; and 2) co ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Single Vector Dual Gene Therapy

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): Primary pulmonary hypertension (PPH) is uniformly fatal and has no known cure. A major pathogenic factor in PPH is decreased synthesis of the vacillator prostaglandin 12 (PG 12) and excess synthesis of the vasoconstrictor prostanoid, thromboxane A2 (TxA2). The investigators have shown in an animal model of acute pulmona ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis

    SBC: Generx+, Inc.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. LONG ACTING NALTREXONE BIODEGRADABLE INJECTABLE GEL

    SBC: James R. Johnson & Associates, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel approach for the treatment of drug abuse using unique and patented biodegradable injectable gel formulations which can control the release of naltrexone. These novel biodegradable get formulations wit maintain therapeutic concentrations of naltrexone for at least 4 week ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. DEVELOPMENT OF MULTI-RECEPTOR LC STATIONARY PHASES

    SBC: MOLECULAR DESIGN INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microliter plates with immobilized target receptors can rapidly reduce thousands of possibilities to hundreds of candidates. The next level of screening has proven to be mor ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. In Vivo System- Screening Anti-Inflammatory Compounds

    SBC: TK TX COMPANY            Topic: N/A

    DESCRIPTION (provided by the applicant): Acute inflammation is necessary for host defense but can also cause organ injury and dysfunction. The NF-kB transcription factor complex is critical for regulation of acute inflammation by controlling expression of a number of key cytokines, adhesion molecules and enzymes. We have generated transgenic mice that express Phot ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government